Mortlock Anna-Marie, Larkin Fintan, Ross Callum C, Gupta Nitin, Sengupta Samrat, Das Mrigendra
Specialist Registrar Forensic Psychiatry, Broadmoor Hospital, West London Mental Health Trust, Crowthorne, UK.
Consultant Forensic Psychiatrist, Broadmoor Hospital, West London Mental Health Trust, Crowthorne, UK.
Ther Adv Psychopharmacol. 2017 May;7(5):169-179. doi: 10.1177/2045125317693513. Epub 2017 Mar 27.
High-security hospital patients are often complex in presentation and are characterized by treatment resistance, medication nonadherence and history of violence. Paliperidone is licensed both as an oral and depot antipsychotic medication in the treatment of schizophrenia. Clinical trials have shown that paliperidone depot is well tolerated with similar efficacy to risperidone depot but with additional practical advantages. Whilst data exist for the effectiveness of paliperidone palmitate (PP), there are no studies involving patients in forensic settings or those with comorbid personality disorder. Our aim was to evaluate the effectiveness of PP on violence, aggression and personality disorder symptoms.
This project was a retrospective service evaluation involving 11 patients, carried out in a high-security hospital. A combination of patient records and interviews with the treating consultant psychiatrist were used to ascertain a Clinical Global Impression (CGI) score, the effect of PP on specific personality disorder symptom domains (cognitive-perceptual, impulsive-behavioural dyscontrol and affective dysregulation) and incidents of violence and aggression. Engagement with occupational and psychological therapies was also evaluated. Metabolic parameters were reviewed.
A total of 6 out of 11 patients continued on PP, most of whom had schizophrenia and dissocial personality disorder with histories of violence. All showed improvement in the CGI score with associated benefits in the three personality symptom domains. Overall, two patients demonstrated a reduction in the risk of violence. There was improvement in engagement with occupational therapy and psychological work. No significant effects on metabolic parameters were noted although hyperprolactinaemia, albeit asymptomatic, was consistently recorded.
This pragmatic service evaluation of a small but complex patient group demonstrated, for the first time, that PP was effective in reducing violence as well as improving personality pathology across all dimensions: a finding which could have significant implications for management of such high-security patients.
高安全级别的医院患者临床表现往往较为复杂,具有治疗抵抗、用药依从性差和暴力史等特征。帕利哌酮作为口服和长效抗精神病药物,被批准用于治疗精神分裂症。临床试验表明,帕利哌酮长效针剂耐受性良好,疗效与利培酮长效针剂相似,但还有其他实际优势。虽然有关于棕榈酸帕利哌酮(PP)有效性的数据,但尚无涉及法医环境中的患者或合并人格障碍患者的研究。我们的目的是评估PP对暴力、攻击行为和人格障碍症状的有效性。
本项目是一项在高安全级别的医院对11名患者进行的回顾性服务评估。结合患者记录和对主治精神科顾问医生的访谈,以确定临床总体印象(CGI)评分、PP对特定人格障碍症状领域(认知 - 感知、冲动 - 行为失控和情感失调)的影响以及暴力和攻击事件。还评估了职业和心理治疗的参与情况。对代谢参数进行了审查。
11名患者中有6名继续使用PP,其中大多数患有精神分裂症和反社会人格障碍且有暴力史。所有患者的CGI评分均有改善,在三个人格症状领域也有相关益处。总体而言,两名患者的暴力风险降低。职业治疗和心理治疗的参与情况有所改善。虽然一直记录到有高泌乳素血症,但无症状,未发现对代谢参数有显著影响。
这项针对一小群复杂患者的务实服务评估首次表明,PP在减少暴力以及改善各方面人格病理学方面是有效的:这一发现可能对这类高安全级别的患者的管理具有重要意义。